Global Plasma Therapy

Plasma Therapy Comprehensive Study by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics (Arthritis, Chronic Tendinitis, Bone Repair & Regeneration), Dermatology (Androgenic Alopecia, Plastic Surgery), Dental, Cardiac Muscle Injury, Nerve Injury, Others), End User (Hospitals, Clinics, Research Institutions), Source (Autologous, Allogenic) Players and Region - Global Market Outlook to 2027

Plasma Therapy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Plasma Therapy
The Plasma therapy, a process of replacing the plasma protein in individuals who are suffering from plasma protein deficiency. It extensively finds application in wound healing, androgenetic alopecia, and face rejuvenation. The growth of this market is mainly attributed to factors such as the advantages offered by PRP treatment, increasing awareness towards PRP therapies; the rising prevalence of musculoskeletal, sports, & orthopedic injuries; and the growing number of cosmetic procedures worldwide. The increase in the number of incidences such as sports injuries and orthopedic diseases includes arthritis and growing androgenic alopecia patients are the major driving agent in the growth of every market.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
UnitValue (USD Million)


The plasma therapy market is a complex and dynamic landscape with significant growth potential. Understanding the key players, competitive factors, and regional variations is crucial for navigating this evolving market and anticipating future trends. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Plasma Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Biolife Plasma Services (United States), Cambryn Biologics LLC (United States), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A.(Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Product Laboratory Ltd.(United Kingdom), China Biologic Products,Inc. (China) and Octapharma (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Green Cross (Switzerland), Japan Blood Products (Japan) and Shanghai RAAS (China).

Segmentation Overview
AMA Research has segmented the market of Global Plasma Therapy market by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF) and Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration], Dermatology [Androgenic Alopecia, Plastic Surgery], Dental, Cardiac Muscle Injury, Nerve Injury and Others) and Region.



On the basis of geography, the market of Plasma Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Plasma Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Source, the sub-segment i.e. Autologous will boost the Plasma Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Demand of Plasma Therapy Deal with COVID 19 Battle and Growing Concern Regarding Skin Health

Market Growth Drivers:
Increase in Aging Population and Rising Number of Orthopedic Disorders and Huge Demand in the Orthopedics Solutions

Challenges:
Varying Prices of Plasma Therapy

Restraints:
Lack of Reimbursement Policies Related to Plasma Therapy and Development in Regenerative Medicine

Opportunities:
Growing Awareness of Plasma Therapy for CORNA Virus Diseases across the Globe and Increasing Number of Androgenic Alopecia Patients

Market Leaders and their expansionary development strategies
In October 2023, The Bill & Melinda Gates Foundation partners with the WHO to launch a global plasma donation program to collect plasma from people who have recovered from COVID-19.
In October 2023, Takeda launches TAKHZYME, a plasma-derived enzyme replacement therapy. Takeda launched TAKHZYME, a new treatment for Pompe disease, a rare metabolic disorder. TAKHZYME utilizes plasma-derived alpha-glucosidase enzyme to address the enzyme deficiency in Pompe patients.
Blood products such as PRP fall under the prevue of FDA's Center for Biologics Evaluation and Research (CBER). CBER is responsible for regulating human cells, tissues, and cellular and tissue-based products. The regulatory process for these products is described in the FDA's 21 CFR 1271 of the Code of Regulations. Under these regulations, certain products including blood products such as PRP are exempt and therefore do not follow the FDA's traditional regulatory pathway that includes animal studies and clinical trials.Finally, despite PRP being exempted, the language in 21 CFR 1271 has caused some recent concern over activated PRP; however to date, the FDA has not attempted to regulate activated PRP. Clinicians using activated PRP should be mindful of these concerns and continued to stay informed.

Key Target Audience
Platelet-rich Plasma (PRP) Manufacturers, Platelet-rich Plasma (PRP) Suppliers, Medical Research Laboratories, Hospitals & Clinics, Academic Medical Centers & Universities, Business Research & Consulting Service Providers and Research & Development (R&D) Companies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
By Application
  • Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration]
  • Dermatology [Androgenic Alopecia, Plastic Surgery]
  • Dental
  • Cardiac Muscle Injury
  • Nerve Injury
  • Others
By End User
  • Hospitals
  • Clinics
  • Research Institutions

By Source
  • Autologous
  • Allogenic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Aging Population
      • 3.2.2. Rising Number of Orthopedic Disorders and Huge Demand in the Orthopedics Solutions
    • 3.3. Market Challenges
      • 3.3.1. Varying Prices of Plasma Therapy
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand of Plasma Therapy Deal with COVID 19 Battle
      • 3.4.2. Growing Concern Regarding Skin Health
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Plasma Therapy, by Type, Application, End User, Source and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Plasma Therapy (Value)
      • 5.2.1. Global Plasma Therapy by: Type (Value)
        • 5.2.1.1. Pure PRP
        • 5.2.1.2. Leucocyte-rich PRP
        • 5.2.1.3. Pure Platelet-rich Fibrin (PRF)
        • 5.2.1.4. Leukocyte-rich Fibrin (L-PRF)
      • 5.2.2. Global Plasma Therapy by: Application (Value)
        • 5.2.2.1. Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration]
        • 5.2.2.2. Dermatology [Androgenic Alopecia, Plastic Surgery]
        • 5.2.2.3. Dental
        • 5.2.2.4. Cardiac Muscle Injury
        • 5.2.2.5. Nerve Injury
        • 5.2.2.6. Others
      • 5.2.3. Global Plasma Therapy by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Research Institutions
      • 5.2.4. Global Plasma Therapy by: Source (Value)
        • 5.2.4.1. Autologous
        • 5.2.4.2. Allogenic
      • 5.2.5. Global Plasma Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Plasma Therapy (Price)
      • 5.3.1. Global Plasma Therapy by: Type (Price)
  • 6. Plasma Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biolife Plasma Services (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cambryn Biologics LLC (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biotest (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CSL Ltd. (Australia)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Grifols International S.A.(Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kedrion S.p.A. (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LFB (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio Product Laboratory Ltd.(United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. China Biologic Products,Inc. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Octapharma (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Plasma Therapy Sale, by Type, Application, End User, Source and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Plasma Therapy (Value)
      • 7.2.1. Global Plasma Therapy by: Type (Value)
        • 7.2.1.1. Pure PRP
        • 7.2.1.2. Leucocyte-rich PRP
        • 7.2.1.3. Pure Platelet-rich Fibrin (PRF)
        • 7.2.1.4. Leukocyte-rich Fibrin (L-PRF)
      • 7.2.2. Global Plasma Therapy by: Application (Value)
        • 7.2.2.1. Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration]
        • 7.2.2.2. Dermatology [Androgenic Alopecia, Plastic Surgery]
        • 7.2.2.3. Dental
        • 7.2.2.4. Cardiac Muscle Injury
        • 7.2.2.5. Nerve Injury
        • 7.2.2.6. Others
      • 7.2.3. Global Plasma Therapy by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Research Institutions
      • 7.2.4. Global Plasma Therapy by: Source (Value)
        • 7.2.4.1. Autologous
        • 7.2.4.2. Allogenic
      • 7.2.5. Global Plasma Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Plasma Therapy (Price)
      • 7.3.1. Global Plasma Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Plasma Therapy: by Type(USD Million)
  • Table 2. Plasma Therapy Pure PRP , by Region USD Million (2016-2021)
  • Table 3. Plasma Therapy Leucocyte-rich PRP , by Region USD Million (2016-2021)
  • Table 4. Plasma Therapy Pure Platelet-rich Fibrin (PRF) , by Region USD Million (2016-2021)
  • Table 5. Plasma Therapy Leukocyte-rich Fibrin (L-PRF) , by Region USD Million (2016-2021)
  • Table 6. Plasma Therapy: by Application(USD Million)
  • Table 7. Plasma Therapy Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration] , by Region USD Million (2016-2021)
  • Table 8. Plasma Therapy Dermatology [Androgenic Alopecia, Plastic Surgery] , by Region USD Million (2016-2021)
  • Table 9. Plasma Therapy Dental , by Region USD Million (2016-2021)
  • Table 10. Plasma Therapy Cardiac Muscle Injury , by Region USD Million (2016-2021)
  • Table 11. Plasma Therapy Nerve Injury , by Region USD Million (2016-2021)
  • Table 12. Plasma Therapy Others , by Region USD Million (2016-2021)
  • Table 13. Plasma Therapy: by End User(USD Million)
  • Table 14. Plasma Therapy Hospitals , by Region USD Million (2016-2021)
  • Table 15. Plasma Therapy Clinics , by Region USD Million (2016-2021)
  • Table 16. Plasma Therapy Research Institutions , by Region USD Million (2016-2021)
  • Table 17. Plasma Therapy: by Source(USD Million)
  • Table 18. Plasma Therapy Autologous , by Region USD Million (2016-2021)
  • Table 19. Plasma Therapy Allogenic , by Region USD Million (2016-2021)
  • Table 20. South America Plasma Therapy, by Country USD Million (2016-2021)
  • Table 21. South America Plasma Therapy, by Type USD Million (2016-2021)
  • Table 22. South America Plasma Therapy, by Application USD Million (2016-2021)
  • Table 23. South America Plasma Therapy, by End User USD Million (2016-2021)
  • Table 24. South America Plasma Therapy, by Source USD Million (2016-2021)
  • Table 25. Brazil Plasma Therapy, by Type USD Million (2016-2021)
  • Table 26. Brazil Plasma Therapy, by Application USD Million (2016-2021)
  • Table 27. Brazil Plasma Therapy, by End User USD Million (2016-2021)
  • Table 28. Brazil Plasma Therapy, by Source USD Million (2016-2021)
  • Table 29. Argentina Plasma Therapy, by Type USD Million (2016-2021)
  • Table 30. Argentina Plasma Therapy, by Application USD Million (2016-2021)
  • Table 31. Argentina Plasma Therapy, by End User USD Million (2016-2021)
  • Table 32. Argentina Plasma Therapy, by Source USD Million (2016-2021)
  • Table 33. Rest of South America Plasma Therapy, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Plasma Therapy, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Plasma Therapy, by End User USD Million (2016-2021)
  • Table 36. Rest of South America Plasma Therapy, by Source USD Million (2016-2021)
  • Table 37. Asia Pacific Plasma Therapy, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Plasma Therapy, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Plasma Therapy, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Plasma Therapy, by End User USD Million (2016-2021)
  • Table 41. Asia Pacific Plasma Therapy, by Source USD Million (2016-2021)
  • Table 42. China Plasma Therapy, by Type USD Million (2016-2021)
  • Table 43. China Plasma Therapy, by Application USD Million (2016-2021)
  • Table 44. China Plasma Therapy, by End User USD Million (2016-2021)
  • Table 45. China Plasma Therapy, by Source USD Million (2016-2021)
  • Table 46. Japan Plasma Therapy, by Type USD Million (2016-2021)
  • Table 47. Japan Plasma Therapy, by Application USD Million (2016-2021)
  • Table 48. Japan Plasma Therapy, by End User USD Million (2016-2021)
  • Table 49. Japan Plasma Therapy, by Source USD Million (2016-2021)
  • Table 50. India Plasma Therapy, by Type USD Million (2016-2021)
  • Table 51. India Plasma Therapy, by Application USD Million (2016-2021)
  • Table 52. India Plasma Therapy, by End User USD Million (2016-2021)
  • Table 53. India Plasma Therapy, by Source USD Million (2016-2021)
  • Table 54. South Korea Plasma Therapy, by Type USD Million (2016-2021)
  • Table 55. South Korea Plasma Therapy, by Application USD Million (2016-2021)
  • Table 56. South Korea Plasma Therapy, by End User USD Million (2016-2021)
  • Table 57. South Korea Plasma Therapy, by Source USD Million (2016-2021)
  • Table 58. Taiwan Plasma Therapy, by Type USD Million (2016-2021)
  • Table 59. Taiwan Plasma Therapy, by Application USD Million (2016-2021)
  • Table 60. Taiwan Plasma Therapy, by End User USD Million (2016-2021)
  • Table 61. Taiwan Plasma Therapy, by Source USD Million (2016-2021)
  • Table 62. Australia Plasma Therapy, by Type USD Million (2016-2021)
  • Table 63. Australia Plasma Therapy, by Application USD Million (2016-2021)
  • Table 64. Australia Plasma Therapy, by End User USD Million (2016-2021)
  • Table 65. Australia Plasma Therapy, by Source USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Plasma Therapy, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Plasma Therapy, by Application USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Plasma Therapy, by End User USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Plasma Therapy, by Source USD Million (2016-2021)
  • Table 70. Europe Plasma Therapy, by Country USD Million (2016-2021)
  • Table 71. Europe Plasma Therapy, by Type USD Million (2016-2021)
  • Table 72. Europe Plasma Therapy, by Application USD Million (2016-2021)
  • Table 73. Europe Plasma Therapy, by End User USD Million (2016-2021)
  • Table 74. Europe Plasma Therapy, by Source USD Million (2016-2021)
  • Table 75. Germany Plasma Therapy, by Type USD Million (2016-2021)
  • Table 76. Germany Plasma Therapy, by Application USD Million (2016-2021)
  • Table 77. Germany Plasma Therapy, by End User USD Million (2016-2021)
  • Table 78. Germany Plasma Therapy, by Source USD Million (2016-2021)
  • Table 79. France Plasma Therapy, by Type USD Million (2016-2021)
  • Table 80. France Plasma Therapy, by Application USD Million (2016-2021)
  • Table 81. France Plasma Therapy, by End User USD Million (2016-2021)
  • Table 82. France Plasma Therapy, by Source USD Million (2016-2021)
  • Table 83. Italy Plasma Therapy, by Type USD Million (2016-2021)
  • Table 84. Italy Plasma Therapy, by Application USD Million (2016-2021)
  • Table 85. Italy Plasma Therapy, by End User USD Million (2016-2021)
  • Table 86. Italy Plasma Therapy, by Source USD Million (2016-2021)
  • Table 87. United Kingdom Plasma Therapy, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Plasma Therapy, by Application USD Million (2016-2021)
  • Table 89. United Kingdom Plasma Therapy, by End User USD Million (2016-2021)
  • Table 90. United Kingdom Plasma Therapy, by Source USD Million (2016-2021)
  • Table 91. Netherlands Plasma Therapy, by Type USD Million (2016-2021)
  • Table 92. Netherlands Plasma Therapy, by Application USD Million (2016-2021)
  • Table 93. Netherlands Plasma Therapy, by End User USD Million (2016-2021)
  • Table 94. Netherlands Plasma Therapy, by Source USD Million (2016-2021)
  • Table 95. Rest of Europe Plasma Therapy, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Plasma Therapy, by Application USD Million (2016-2021)
  • Table 97. Rest of Europe Plasma Therapy, by End User USD Million (2016-2021)
  • Table 98. Rest of Europe Plasma Therapy, by Source USD Million (2016-2021)
  • Table 99. MEA Plasma Therapy, by Country USD Million (2016-2021)
  • Table 100. MEA Plasma Therapy, by Type USD Million (2016-2021)
  • Table 101. MEA Plasma Therapy, by Application USD Million (2016-2021)
  • Table 102. MEA Plasma Therapy, by End User USD Million (2016-2021)
  • Table 103. MEA Plasma Therapy, by Source USD Million (2016-2021)
  • Table 104. Middle East Plasma Therapy, by Type USD Million (2016-2021)
  • Table 105. Middle East Plasma Therapy, by Application USD Million (2016-2021)
  • Table 106. Middle East Plasma Therapy, by End User USD Million (2016-2021)
  • Table 107. Middle East Plasma Therapy, by Source USD Million (2016-2021)
  • Table 108. Africa Plasma Therapy, by Type USD Million (2016-2021)
  • Table 109. Africa Plasma Therapy, by Application USD Million (2016-2021)
  • Table 110. Africa Plasma Therapy, by End User USD Million (2016-2021)
  • Table 111. Africa Plasma Therapy, by Source USD Million (2016-2021)
  • Table 112. North America Plasma Therapy, by Country USD Million (2016-2021)
  • Table 113. North America Plasma Therapy, by Type USD Million (2016-2021)
  • Table 114. North America Plasma Therapy, by Application USD Million (2016-2021)
  • Table 115. North America Plasma Therapy, by End User USD Million (2016-2021)
  • Table 116. North America Plasma Therapy, by Source USD Million (2016-2021)
  • Table 117. United States Plasma Therapy, by Type USD Million (2016-2021)
  • Table 118. United States Plasma Therapy, by Application USD Million (2016-2021)
  • Table 119. United States Plasma Therapy, by End User USD Million (2016-2021)
  • Table 120. United States Plasma Therapy, by Source USD Million (2016-2021)
  • Table 121. Canada Plasma Therapy, by Type USD Million (2016-2021)
  • Table 122. Canada Plasma Therapy, by Application USD Million (2016-2021)
  • Table 123. Canada Plasma Therapy, by End User USD Million (2016-2021)
  • Table 124. Canada Plasma Therapy, by Source USD Million (2016-2021)
  • Table 125. Mexico Plasma Therapy, by Type USD Million (2016-2021)
  • Table 126. Mexico Plasma Therapy, by Application USD Million (2016-2021)
  • Table 127. Mexico Plasma Therapy, by End User USD Million (2016-2021)
  • Table 128. Mexico Plasma Therapy, by Source USD Million (2016-2021)
  • Table 129. Plasma Therapy: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Plasma Therapy: by Type(USD Million)
  • Table 141. Plasma Therapy Pure PRP , by Region USD Million (2022-2027)
  • Table 142. Plasma Therapy Leucocyte-rich PRP , by Region USD Million (2022-2027)
  • Table 143. Plasma Therapy Pure Platelet-rich Fibrin (PRF) , by Region USD Million (2022-2027)
  • Table 144. Plasma Therapy Leukocyte-rich Fibrin (L-PRF) , by Region USD Million (2022-2027)
  • Table 145. Plasma Therapy: by Application(USD Million)
  • Table 146. Plasma Therapy Orthopedics [Arthritis, Chronic Tendinitis, Bone Repair & Regeneration] , by Region USD Million (2022-2027)
  • Table 147. Plasma Therapy Dermatology [Androgenic Alopecia, Plastic Surgery] , by Region USD Million (2022-2027)
  • Table 148. Plasma Therapy Dental , by Region USD Million (2022-2027)
  • Table 149. Plasma Therapy Cardiac Muscle Injury , by Region USD Million (2022-2027)
  • Table 150. Plasma Therapy Nerve Injury , by Region USD Million (2022-2027)
  • Table 151. Plasma Therapy Others , by Region USD Million (2022-2027)
  • Table 152. Plasma Therapy: by End User(USD Million)
  • Table 153. Plasma Therapy Hospitals , by Region USD Million (2022-2027)
  • Table 154. Plasma Therapy Clinics , by Region USD Million (2022-2027)
  • Table 155. Plasma Therapy Research Institutions , by Region USD Million (2022-2027)
  • Table 156. Plasma Therapy: by Source(USD Million)
  • Table 157. Plasma Therapy Autologous , by Region USD Million (2022-2027)
  • Table 158. Plasma Therapy Allogenic , by Region USD Million (2022-2027)
  • Table 159. South America Plasma Therapy, by Country USD Million (2022-2027)
  • Table 160. South America Plasma Therapy, by Type USD Million (2022-2027)
  • Table 161. South America Plasma Therapy, by Application USD Million (2022-2027)
  • Table 162. South America Plasma Therapy, by End User USD Million (2022-2027)
  • Table 163. South America Plasma Therapy, by Source USD Million (2022-2027)
  • Table 164. Brazil Plasma Therapy, by Type USD Million (2022-2027)
  • Table 165. Brazil Plasma Therapy, by Application USD Million (2022-2027)
  • Table 166. Brazil Plasma Therapy, by End User USD Million (2022-2027)
  • Table 167. Brazil Plasma Therapy, by Source USD Million (2022-2027)
  • Table 168. Argentina Plasma Therapy, by Type USD Million (2022-2027)
  • Table 169. Argentina Plasma Therapy, by Application USD Million (2022-2027)
  • Table 170. Argentina Plasma Therapy, by End User USD Million (2022-2027)
  • Table 171. Argentina Plasma Therapy, by Source USD Million (2022-2027)
  • Table 172. Rest of South America Plasma Therapy, by Type USD Million (2022-2027)
  • Table 173. Rest of South America Plasma Therapy, by Application USD Million (2022-2027)
  • Table 174. Rest of South America Plasma Therapy, by End User USD Million (2022-2027)
  • Table 175. Rest of South America Plasma Therapy, by Source USD Million (2022-2027)
  • Table 176. Asia Pacific Plasma Therapy, by Country USD Million (2022-2027)
  • Table 177. Asia Pacific Plasma Therapy, by Type USD Million (2022-2027)
  • Table 178. Asia Pacific Plasma Therapy, by Application USD Million (2022-2027)
  • Table 179. Asia Pacific Plasma Therapy, by End User USD Million (2022-2027)
  • Table 180. Asia Pacific Plasma Therapy, by Source USD Million (2022-2027)
  • Table 181. China Plasma Therapy, by Type USD Million (2022-2027)
  • Table 182. China Plasma Therapy, by Application USD Million (2022-2027)
  • Table 183. China Plasma Therapy, by End User USD Million (2022-2027)
  • Table 184. China Plasma Therapy, by Source USD Million (2022-2027)
  • Table 185. Japan Plasma Therapy, by Type USD Million (2022-2027)
  • Table 186. Japan Plasma Therapy, by Application USD Million (2022-2027)
  • Table 187. Japan Plasma Therapy, by End User USD Million (2022-2027)
  • Table 188. Japan Plasma Therapy, by Source USD Million (2022-2027)
  • Table 189. India Plasma Therapy, by Type USD Million (2022-2027)
  • Table 190. India Plasma Therapy, by Application USD Million (2022-2027)
  • Table 191. India Plasma Therapy, by End User USD Million (2022-2027)
  • Table 192. India Plasma Therapy, by Source USD Million (2022-2027)
  • Table 193. South Korea Plasma Therapy, by Type USD Million (2022-2027)
  • Table 194. South Korea Plasma Therapy, by Application USD Million (2022-2027)
  • Table 195. South Korea Plasma Therapy, by End User USD Million (2022-2027)
  • Table 196. South Korea Plasma Therapy, by Source USD Million (2022-2027)
  • Table 197. Taiwan Plasma Therapy, by Type USD Million (2022-2027)
  • Table 198. Taiwan Plasma Therapy, by Application USD Million (2022-2027)
  • Table 199. Taiwan Plasma Therapy, by End User USD Million (2022-2027)
  • Table 200. Taiwan Plasma Therapy, by Source USD Million (2022-2027)
  • Table 201. Australia Plasma Therapy, by Type USD Million (2022-2027)
  • Table 202. Australia Plasma Therapy, by Application USD Million (2022-2027)
  • Table 203. Australia Plasma Therapy, by End User USD Million (2022-2027)
  • Table 204. Australia Plasma Therapy, by Source USD Million (2022-2027)
  • Table 205. Rest of Asia-Pacific Plasma Therapy, by Type USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Plasma Therapy, by Application USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Plasma Therapy, by End User USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Plasma Therapy, by Source USD Million (2022-2027)
  • Table 209. Europe Plasma Therapy, by Country USD Million (2022-2027)
  • Table 210. Europe Plasma Therapy, by Type USD Million (2022-2027)
  • Table 211. Europe Plasma Therapy, by Application USD Million (2022-2027)
  • Table 212. Europe Plasma Therapy, by End User USD Million (2022-2027)
  • Table 213. Europe Plasma Therapy, by Source USD Million (2022-2027)
  • Table 214. Germany Plasma Therapy, by Type USD Million (2022-2027)
  • Table 215. Germany Plasma Therapy, by Application USD Million (2022-2027)
  • Table 216. Germany Plasma Therapy, by End User USD Million (2022-2027)
  • Table 217. Germany Plasma Therapy, by Source USD Million (2022-2027)
  • Table 218. France Plasma Therapy, by Type USD Million (2022-2027)
  • Table 219. France Plasma Therapy, by Application USD Million (2022-2027)
  • Table 220. France Plasma Therapy, by End User USD Million (2022-2027)
  • Table 221. France Plasma Therapy, by Source USD Million (2022-2027)
  • Table 222. Italy Plasma Therapy, by Type USD Million (2022-2027)
  • Table 223. Italy Plasma Therapy, by Application USD Million (2022-2027)
  • Table 224. Italy Plasma Therapy, by End User USD Million (2022-2027)
  • Table 225. Italy Plasma Therapy, by Source USD Million (2022-2027)
  • Table 226. United Kingdom Plasma Therapy, by Type USD Million (2022-2027)
  • Table 227. United Kingdom Plasma Therapy, by Application USD Million (2022-2027)
  • Table 228. United Kingdom Plasma Therapy, by End User USD Million (2022-2027)
  • Table 229. United Kingdom Plasma Therapy, by Source USD Million (2022-2027)
  • Table 230. Netherlands Plasma Therapy, by Type USD Million (2022-2027)
  • Table 231. Netherlands Plasma Therapy, by Application USD Million (2022-2027)
  • Table 232. Netherlands Plasma Therapy, by End User USD Million (2022-2027)
  • Table 233. Netherlands Plasma Therapy, by Source USD Million (2022-2027)
  • Table 234. Rest of Europe Plasma Therapy, by Type USD Million (2022-2027)
  • Table 235. Rest of Europe Plasma Therapy, by Application USD Million (2022-2027)
  • Table 236. Rest of Europe Plasma Therapy, by End User USD Million (2022-2027)
  • Table 237. Rest of Europe Plasma Therapy, by Source USD Million (2022-2027)
  • Table 238. MEA Plasma Therapy, by Country USD Million (2022-2027)
  • Table 239. MEA Plasma Therapy, by Type USD Million (2022-2027)
  • Table 240. MEA Plasma Therapy, by Application USD Million (2022-2027)
  • Table 241. MEA Plasma Therapy, by End User USD Million (2022-2027)
  • Table 242. MEA Plasma Therapy, by Source USD Million (2022-2027)
  • Table 243. Middle East Plasma Therapy, by Type USD Million (2022-2027)
  • Table 244. Middle East Plasma Therapy, by Application USD Million (2022-2027)
  • Table 245. Middle East Plasma Therapy, by End User USD Million (2022-2027)
  • Table 246. Middle East Plasma Therapy, by Source USD Million (2022-2027)
  • Table 247. Africa Plasma Therapy, by Type USD Million (2022-2027)
  • Table 248. Africa Plasma Therapy, by Application USD Million (2022-2027)
  • Table 249. Africa Plasma Therapy, by End User USD Million (2022-2027)
  • Table 250. Africa Plasma Therapy, by Source USD Million (2022-2027)
  • Table 251. North America Plasma Therapy, by Country USD Million (2022-2027)
  • Table 252. North America Plasma Therapy, by Type USD Million (2022-2027)
  • Table 253. North America Plasma Therapy, by Application USD Million (2022-2027)
  • Table 254. North America Plasma Therapy, by End User USD Million (2022-2027)
  • Table 255. North America Plasma Therapy, by Source USD Million (2022-2027)
  • Table 256. United States Plasma Therapy, by Type USD Million (2022-2027)
  • Table 257. United States Plasma Therapy, by Application USD Million (2022-2027)
  • Table 258. United States Plasma Therapy, by End User USD Million (2022-2027)
  • Table 259. United States Plasma Therapy, by Source USD Million (2022-2027)
  • Table 260. Canada Plasma Therapy, by Type USD Million (2022-2027)
  • Table 261. Canada Plasma Therapy, by Application USD Million (2022-2027)
  • Table 262. Canada Plasma Therapy, by End User USD Million (2022-2027)
  • Table 263. Canada Plasma Therapy, by Source USD Million (2022-2027)
  • Table 264. Mexico Plasma Therapy, by Type USD Million (2022-2027)
  • Table 265. Mexico Plasma Therapy, by Application USD Million (2022-2027)
  • Table 266. Mexico Plasma Therapy, by End User USD Million (2022-2027)
  • Table 267. Mexico Plasma Therapy, by Source USD Million (2022-2027)
  • Table 268. Plasma Therapy: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Plasma Therapy: by Type USD Million (2016-2021)
  • Figure 5. Global Plasma Therapy: by Application USD Million (2016-2021)
  • Figure 6. Global Plasma Therapy: by End User USD Million (2016-2021)
  • Figure 7. Global Plasma Therapy: by Source USD Million (2016-2021)
  • Figure 8. South America Plasma Therapy Share (%), by Country
  • Figure 9. Asia Pacific Plasma Therapy Share (%), by Country
  • Figure 10. Europe Plasma Therapy Share (%), by Country
  • Figure 11. MEA Plasma Therapy Share (%), by Country
  • Figure 12. North America Plasma Therapy Share (%), by Country
  • Figure 13. Global Plasma Therapy: by Type USD/Units (2016-2021)
  • Figure 14. Global Plasma Therapy share by Players 2021 (%)
  • Figure 15. Global Plasma Therapy share by Players (Top 3) 2021(%)
  • Figure 16. Global Plasma Therapy share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Biolife Plasma Services (United States) Revenue, Net Income and Gross profit
  • Figure 19. Biolife Plasma Services (United States) Revenue: by Geography 2021
  • Figure 20. Cambryn Biologics LLC (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cambryn Biologics LLC (United States) Revenue: by Geography 2021
  • Figure 22. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Biotest (Germany) Revenue: by Geography 2021
  • Figure 24. CSL Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 25. CSL Ltd. (Australia) Revenue: by Geography 2021
  • Figure 26. Grifols International S.A.(Spain) Revenue, Net Income and Gross profit
  • Figure 27. Grifols International S.A.(Spain) Revenue: by Geography 2021
  • Figure 28. Kedrion S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 29. Kedrion S.p.A. (Italy) Revenue: by Geography 2021
  • Figure 30. LFB (France) Revenue, Net Income and Gross profit
  • Figure 31. LFB (France) Revenue: by Geography 2021
  • Figure 32. Bio Product Laboratory Ltd.(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Bio Product Laboratory Ltd.(United Kingdom) Revenue: by Geography 2021
  • Figure 34. China Biologic Products,Inc. (China) Revenue, Net Income and Gross profit
  • Figure 35. China Biologic Products,Inc. (China) Revenue: by Geography 2021
  • Figure 36. Octapharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Octapharma (Switzerland) Revenue: by Geography 2021
  • Figure 38. Global Plasma Therapy: by Type USD Million (2022-2027)
  • Figure 39. Global Plasma Therapy: by Application USD Million (2022-2027)
  • Figure 40. Global Plasma Therapy: by End User USD Million (2022-2027)
  • Figure 41. Global Plasma Therapy: by Source USD Million (2022-2027)
  • Figure 42. South America Plasma Therapy Share (%), by Country
  • Figure 43. Asia Pacific Plasma Therapy Share (%), by Country
  • Figure 44. Europe Plasma Therapy Share (%), by Country
  • Figure 45. MEA Plasma Therapy Share (%), by Country
  • Figure 46. North America Plasma Therapy Share (%), by Country
  • Figure 47. Global Plasma Therapy: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Biolife Plasma Services (United States)
  • Cambryn Biologics LLC (United States)
  • Biotest (Germany)
  • CSL Ltd. (Australia)
  • Grifols International S.A.(Spain)
  • Kedrion S.p.A. (Italy)
  • LFB (France)
  • Bio Product Laboratory Ltd.(United Kingdom)
  • China Biologic Products,Inc. (China)
  • Octapharma (Switzerland)
Additional players considered in the study are as follows:
Green Cross (Switzerland) , Japan Blood Products (Japan) , Shanghai RAAS (China)
Select User Access Type

Key Highlights of Report


Jan 2024 235 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Plasma Therapy Quantitative research analysis
Global Plasma Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Biolife Plasma Services (United States), Cambryn Biologics LLC (United States), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A.(Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Product Laboratory Ltd.(United Kingdom), China Biologic Products,Inc. (China) and Octapharma (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Demand of Plasma Therapy Deal with COVID 19 Battle " is seen as one of major influencing trends for Plasma Therapy Market during projected period 2021-2027.
The Plasma Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Plasma Therapy Report?

Have a Query? Click Here

Other Related Reports

Poultry Bacteriology Diagnostics Comprehensive Study by Type (ELISA Test, PCR Test, Others), Application (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Mycoplasmosis, Avian Pasteurel...
$ 3750
Cold Pain Therapy Comprehensive Study by Type (OTC-Based Products, Prescription-Based Products), Application (Musculoskeletal Disorders, Sport Medicine, Physical Therapy, Post Operative Therapy, Post...
$ 3450
Synovial Sarcoma Treatment Comprehensive Study by Type (High-grade, Low-grade, Translocation-associated), End Users (Hospitals, Specialty Clinics, Oncology Centers, Other), Treatment (Surgery, Anti-A...
$ 3500
Hairy Cell Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy {Cladribine, Pentostatin}, Biologic Therapy {Rituximab, Interferon}, Splenectomy), Application (Hospital, Clinic, Others), D...
$ 3750
Medulloblastoma Drug Comprehensive Study by Type (Dianhydrogalactitol, IMP-5471, Ipilimumab, Indoximod, Others), Application (Hospital, Clinic, Others), Treatment (Surgery, Radiation Therapy, Chemoth...
$ 3350
Oncolytic Virus Comprehensive Study by Type (Natural Viruses (wild type, Naturally Variant Strains of Weak Viruses), Genetically Modified Virus Strains), Application (Breast Cancer, Lung Cancer, Pros...
$ 3650